NORML Home / News Archive / 2004 / Canada Set To Authorize Prescription Use Of First-Ever Medical Cannabis Spray: "Ottawa, Ontario: Health Canada has issued a 'Qualifying Notice' for the approval of Sativex, an oral spray consisting of natural cannabis extracts, for the treatment of neuropathic pain associated with Multiple Sclerosis (MS). Health Canada is expected to finalize marketing authorization for Sativex by early 2005.
Produced by the British biotechnology firm GW Pharmaceuticals, Sativex is a whole plant medicinal cannabis extract containing precise doses of the cannabinoids THC and cannabidiol (CBD). In clinical trials, Sativex has been demonstrated to alleviate numerous MS-associated symptoms compared to placebo, including pain, muscle spasms, and bladder incontinence."
Aucun commentaire:
Publier un commentaire